TABLE 1.

Quantification of reactivity to DMS in RNA analogues in the presence of aminoglycosides

Aminoglycoside	Nucleotide position	Relative reactivitya to DMS in the presence of the indicated concn of aminoglycoside
		RNA oligonucleotide carrying 1555A				RNA oligonucleotide carrying 1555G
		0.1 μM	1 μM	10 μM	100 μM	0.1 μM	1 μM	10 μM	100 μM
Paromomycin	1553	122.8	109.0	95.2	79.2	78.1	73.9	60.5	50.8
	1555	118.0	94.4	82.5	67.7	74.5	72.1	59.0	59.1
	1556	142.1	138.5	139.5	113.9	115.1	95.1	76.8	73.9
Neomycin	1553	110.4	74.8	74.7	65.9	56.3	59.1	63.7	56.2
	1555	101.6	85.5	62.9	62.7	56.4	56.0	55.0	51.6
	1556	107.8	86.5	87.7	71.3	63.9	66.1	65.7	58.6
Gentamicin	1553	51.8	50.2	58.8	48.4	54.5	50.1	53.9	54.1
	1555	85.0	75.1	77.9	69.0	62.2	58.2	56.2	55.9
	1556	139.9	135.0	172.8	124.1	65.8	70.3	74.0	78.1
Tobramycin	1553	95.5	94.6	67.6	97.5	86.2	73.7	56.4	49.8
	1555	86.7	71.9	59.5	59.0	77.7	60.5	48.9	53.6
	1556	95.2	112.5	85.0	97.0	81.2	68.2	58.1	68.3
Kanamycin	1553	93.9	92.9	70.3	75.6	66.1	64.3	69.8	66.0
	1555	89.4	84.7	70.3	62.3	65.0	59.9	56.6	52.8
	1556	111.6	101.7	86.6	109.0	72.7	64.3	73.6	68.3
Streptomycin	1553	69.7	59.6	73.7	68.8	68.1	63.7	51.3	53.2
	1555	79.4	69.5	72.9	66.9	69.8	67.1	56.2	52.3
	1556	93.9	79.7	84.2	88.3	81.0	83.0	67.1	64.5

^aThe relative reactivities to DMS for each nucleotide in RNA analogues carrying the A1555G mutation or wild-type 12S rRNA sequence in the presence of aminoglycosides were expressed as percentages of the average values for the corresponding band in the corresponding RNA analogue in the absence of drugs in each gel. Quantifications of the relative reactivities were based on three independent experiments.